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Abstract 
In 1995, the steroid receptor coactivator-1 (SRC-1) was identified as the first authentic 
steroid receptor coactivator. Since then, the SRC proteins have remained at the epicenter of 
coregulator  biology,  molecular  endocrinology  and  endocrine-related  cancer.  Cumulative 
works on SRC-1 have shown that it is primarily a nuclear receptor coregulator and functions 
to construct highly specific enzymatic protein complexes which can execute efficient and 
successful transcriptional activation of designated target genes. The versatile nature of SRC-1 
enables it to respond to steroid dependent and steroid independent stimulation, allowing it to 
bind  across  many  families of  transcription  factors  to  orchestrate and  regulate  complex 
physiological reactions. This review highlights the multiple functions of SRC-1 in the devel-
opment and maintenance of normal tissue functions as well as its major role in mediating 
hormone receptor responsiveness. Insights from genetically manipulated mouse models and 
clinical data suggest SRC-1 is significantly overexpressed in many cancers, in particular, can-
cers of the reproductive tissues. SRC-1 has been associated with cellular proliferation and 
tumor growth but its major tumorigenic contributions are promotion and execution of breast 
cancer metastasis and mediation of resistance to endocrine therapies. The ability of SRC-1 to 
coordinate multiple signaling pathways makes it an important player in tumor cells’ escape of 
targeted therapy. 
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Introduction 
Coregulator proteins were initially thought to be 
mere “acceptor proteins” that facilitated the interac-
tion of specific ligand-bound nuclear receptors with 
general  transcriptional  machinery  [1].  Over  the  last 
seventeen years, however, complex and essential roles 
for  a  cohort  of  over  350  coactivator  proteins  have 
steadily emerged [2]. Coregulator proteins have the 
uncanny ability to bind across unrelated families of 
transcription  factors  and  coordinately  facilitate  the 
efficient  and  successful  transcriptional  activity  of 
multiple target genes. 
The  nuclear  receptors  (NRs)  comprise  a  large 
superfamily of proteins that bind as homo- or hetero-
dimers  to  specific  DNA  elements  in  order  to  elicit 
transcriptional activation of target genes. Specifically, 
the  steroid  nuclear  receptors  or  class  I  NRs  are  re-
cruited  to  gene  promoters  upon  the  binding  of  a 
high-affinity  ligand,  which  induce  conformational 
changes in the NR essential for its activity. The sig-
nificance  of  NR  coregulator  proteins  came  to  light 
when  in  vitro  experiments  using  purified  NRs  and 
basal transcription factors proved relatively incapable 
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of inducing transcriptional activation on their own [3, 
4].  Furthermore,  NRs  were  also  shown  to  compete 
with  each  other  for  these  essential  coregulators  as 
overexpression  of  one  NR  appeared  to  inhibit  the 
transactivation function of another [5]. 
The  steroid  receptor  coactivator  1  (SRC-1,  also 
known as NCOA1) was first discovered in 1995 in a 
yeast two-hybrid screen based on its interaction with 
the  ligand  binding  domain  (LBD)  of  progesterone 
receptor  (PR)  [6].  This  work  represented  the  first 
cloning of an authentic NR coactivator. SRC-1 had the 
ability  to  interact  with  and  coactivate  NRs  in  the 
presence of hormones. These SRC-1 coregulated NRs 
include  PR,  glucocorticoid  receptor  (GR),  estrogen 
receptor alpha (ERα), thyroid receptor (TR), retinoid X 
receptor (RXR), hepatocyte nuclear factor 4 (HNF4α) 
and  peroxisome  proliferator-activated  receptor  γ 
(PPARγ) [6-8]. The binding affinity of SRC-1 for these 
NRs has been shown to vary depending on where it 
specifically binds the NR. SRC-1 can bind NRs via its 
central  region  or  less  commonly  via  its  C-terminal 
domain. The central domain of SRC-1 has been shown 
to be unable to bind to AR and only exhibits a poor 
binding affinity for GR. In contrast, the C-terminus of 
SRC-1 exhibits a poor binding affinity for ER, VDR, 
RAR and TR, relative to its central domain [9]. Fur-
thermore,  fluorescence  resonance  energy  transfer 
(FRET)  experiments  have  shown  that  the  complex 
formed between ERα and SRC-1 exhibited a particu-
larly  high  affinity  binding,  compared  to  other 
SRC-1/NR complexes [10]. Importantly, SRC-1 coac-
tivator  activity  is  not  limited  to  the  transcriptional 
co-activation of NRs, SRC-1 is also capable of coacti-
vating other non steroidal transcription factors such 
as AP-1, serum response factor, NF, Ets2, PEA3 and 
HOXC11 [11-17]. 
SRC-1 is the founding member of the p160 SRC 
family which also includes SRC-2 (NCOA2, TIF2 or 
GRIP1)  and  SRC-3  (AIB1,  p/CIP,  ACTR,  RAC3  or 
NCOA3) [18, 19]. Each member is approximately 160 
kDa in size and their sequences are largely conserved 
across family members and also across species. The 
p160 SRC family members also have overlapping co-
activator  functions  and  transfection  assays  have 
shown that all three can coactivate GR, PR and ERα 
[6]. The potential for functional redundancy among 
the  three  members  may  serve  to  ensure  a  safety 
mechanism in the regulation of numerous important 
biological processes that are associated with NR sig-
naling. 
Structural and Functional Domains of 
SRC-1 
NR coactivators are unable to bind directly to the 
DNA. Instead they form  multiple contacts  with the 
NR and with each other in multi-protein cooperative 
coactivator complexes. Initial investigations  into co-
activator  complexes  reported  that  steady-state  SRC 
complexes consist of six to ten stably associated pro-
teins and many more loosely-bound proteins [20]. The 
versatile structural domains of SRC-1 and the other 
SRC family members grant them a central position in 
such  complexes,  from  which  they  regulate  multiple 
biochemical processes critical for the successful exe-
cution of transcription. 
1. The N-terminal domain 
The SRC-1 protein structure is composed of sev-
eral  distinct  functional  domains.  The  N-terminus 
contains a basic helix-loop-helix-Per/Ah receptor nu-
clear translocation/Sim (bHLH/PAS) motif and is the 
most conserved region among the SRC family mem-
bers with 75% similarity [4]. The bHLH/PAS domain 
is important for the protein-protein interactions that 
recruit  secondary  coactivators  or  co-coactivators  to 
maximize the transcriptional activity of NRs (Figure 
1). The domain is also important for the dimerization 
of SRC proteins and for the differential regulation of 
target genes [21, 22]. Nonetheless, cell-free chromatin 
transcription  assays  have  shown  that,  although  the 
bHLH/PAS domain can maximize the transcriptional 
potential of a complex, transcription can still occur in 
its absence. For instance, an N-terminal-deleted form 
of SRC-1 exhibits coactivation of PR-dependent tran-
scription comparable to that of wild-type SRC-1 [23]. 
More recent studies have shown that the bHLH/PAS 
domain also has a bipartite nuclear localization signal 
(NLS) essential for the import and export of the SRC 
proteins  between  the  nucleus  and  the  cytoplasm. 
Mutation of two key residues Lys 17 (K17) and Arg 18 
(R18)  within  this  region  of  the  bHLH/PAS  domain 
prevented nuclear localization of all three p160 family 
members [24].  
2. The nuclear receptor interaction domain 
(NRID) 
The central region of the SRC-1 protein contains 
the nuclear receptor interaction domain (NRID). This 
domain contains three α-helical LXXLL (L, leucine; X, 
any amino acid) motifs which are essential for inter-
action of SRC-1 with its specific NRs (Figure 1) [25, 
26]. These LXXLL motifs are the most common feature 
among the highly diverse group of coregulators [27]. 
Distinct  LXXLL  motifs  along  with  their  specific 
flanking sequences exhibit different binding affinities 
for different NRs inferring that NRs may prefer one 
LXXLL motif over another in the same coactivator or 
even prefer one coactivator over another [27, 28].  Int. J. Biol. Sci. 2012, 8 
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Figure 1. SRC-1-mediated coactivation of NRs. To exert its coactivation function in transcription, SRC-1 interacts with hormone 
(H)-bound nuclear receptors (NRs) to recruit other components of a large coactivator complex to the hormone response elements of a 
target gene. Specifically, SRC-1 binds NRs through one of its three LXXLL motifs (L1, L2 and L3) in the NR interaction domain (NRID) and 
interacts with CBP and p300 through its activation domain 1 (AD1), with CARM1 and PRMT1 through its AD2 and with SWI/SNF through 
its AD3. p/CAF is a p300/CBP-associated factor. CBP, p300 and p/CAF are histone acetyltransferases. CARM1 and PRMT1 are histone 
methyltransferases. RHA is a RNA helicase. SWI/SNF is an ATP-dependent chromatin remodeling complex. The formation of such a 
coactivator complex results in chromatin remodeling and bridges the hormone-activated NRs with the general transcription machinery 
for transcriptional activation of their specific target genes. bHLH/PAS: basic helix-loop-helix-Per/Ah receptor nuclear translocation/Sim 
motif; Ac: acetylation; Me: methylation; TBP, TATA-binding protein. 
 
 
The  LXXLL  core  motifs  in  SRC-1  have  shown 
distinct preferences for steroid and retinoid receptors. 
In  particular,  a  hydrophobic  residue  at  position  -1 
relative to the first conserved leucine and a nonhy-
drophobic residue at position +2 have a strong impact 
on the affinity and selectivity of the coactivator motifs 
to bind to certain NR LBDs [29]. 
Secondary structural analysis of the central re-
gion shows that LXXLL motifs form an amphipathic 
α-helix which binds to a hydrophobic cleft that forms 
in the ligand-binding domains of NRs once ligands 
have  bound  [30].  Interactions  between  the  leucine 
residues  of  the  LXXLL  motif  and  the  hydrophobic 
cleft stabilize the SRC-1/NR complex [31]. Mutation 
of these leucine residues have been shown to inhibit 
the  binding  of  SRC-1  to  the  ERα  LBD  in vitro  and 
SRC-1-mediated activation of ERα in vivo [26]. 
3. The C-terminal domain 
The C terminal domain of SRC-1 contains two 
intrinsic transactivation domains: AD1 and AD2. The 
AD1 domain is required for the recruitment of sec-
ondary coactivators, such as cAMP response element 
binding  protein  (CREB)-binding  protein  (CBP)  and 
the  histone  acetyltransferase  p300  (Figure  1).  Once 
SRC-1 has complexed with its ligand-bound receptor 
at the DNA, it must bring in additional proteins such 
as CBP and p300 to acetylate histone residues within 
the enhancer and promoter regions of the target gene 
so  that  transcription  can  successfully  occur.  In vitro 
transcription assays from chromatin-assembled tem-
plates have demonstrated that the interaction of p300 
with  the  AD1  domain  of  SRC-1  is  essential  for 
SRC-1-mediated  coactivation  of  ERα  [32].  Further-Int. J. Biol. Sci. 2012, 8 
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more,  observations  from  the  p300  protein  structure 
have confirmed that it is the SRC-1 interacting domain 
and not the ERα-interacting domain, that is essential 
for  p300-mediated  coactivation  of  ERα  [32].  Addi-
tional  experiments  have  demonstrated  that  the  C 
terminus of SRC-1 and also SRC-3 have intrinsic his-
tone acetyltransferase activity (HAT); however, it re-
mains unclear if such HAT activity is significant for 
target gene activation as the SRC-1 intrinsic HAT ac-
tivity is much weaker than that in the CBP/p300 pro-
teins [33, 34]. SRC-1 also uses its AD1 domain to in-
teract  directly  or  indirectly  via  CBP/p300  with  an-
other  HAT  protein  known  as  p/CAF  (Figure  1). 
p/CAF  primarily  acetylates  histone  H3  and  H4  to 
further facilitate chromatin remodeling at the site of 
NR target genes [35]. 
The AD1 domain is also responsible for interac-
tions  with  the  general  transcription  machinery  [36, 
37]. The AD1 has three LXXLL-like motifs and if any 
of these motifs are mutated there is a consequential 
disruption  of  SRC-1  interaction  with  the  general 
transcription machinery [38, 39]. Additionally, RNA 
helicase  A  (RHA)  may  be  recruited  to  the 
SRC-1–CBP/p300  complex  at  the  AD1  domain  and 
interacts with RNA polymerase II, bringing NRs into 
touch with the general transcription machinery (Fig-
ure 1) [40]. 
The AD2 domain of SRC-1 recruits histone me-
thyl  transferases  (HMTs)  such  as  coactiva-
tor-associated arginine methyltransferase 1 (CARM1) 
and protein arginine N-methyltransferase 1 (PRMT1) 
(Figure 1). CARM1 is a histone H3 specific arginine 
methyltransferase, which specifically methylates his-
tone H3 at arginines 2, 17, and 26. CARM1 can only 
enhance  NR  transcription  in  the  presence  of  a  SRC 
protein and mutation of its binding domain will re-
duce  its  HMT  activity  and  ability  to  act  as  a 
co-coactivator [41]. There appears to be a cooperative 
effort at play between the recruited co-coactivators as 
CBP-mediated acetylation of H3K18 has been shown 
to promote CARM1-mediated methylation of H3K17 
[42]. CARM1 and PRMT1 can also act in synergy to 
enhance transcription [41]. PRMT1 acts on a different 
substrate to CARM1 and specifically methylates H4 at 
arginine  3  [43].  Again  cooperative  crosstalk  is  ob-
served  between  PRMT1  and  p300  as 
PRMT1-mediated H4 methylation at arginine 3 facili-
tates the subsequent acetylation of histone H4 tails by 
p300 [44]. 
Recently,  a  third  activation  domain  (AD3)  has 
been identified in  the bHLH/PAS domain. This re-
gion  also  binds  co-coactivators  for  NR  mediated 
transcription.  Many  of  these  AD3  co-coactivators 
function synergistically with the other co-coactivators 
that bind to the AD1 and AD2 domains of SRCs [45]. 
The co-coactivator BAF57, a subunit of the SWI/SNF 
ATP-dependent  chromatin  remodeling  complex, 
binds to SRC-1 within its AD3 domain and potentiates 
SRC-mediated coactivation [46]. 
4. Post translational modification of SRC-1 
 SRC  proteins  are  regulated  by  numerous  post 
translational modifications (PTMs), which are crucial 
for determining protein stability, transcription factor 
interaction  specificity  and  transcriptional  activation 
[47]. In addition to ER, SRC-1 is regulated via alterna-
tive cellular signaling pathways which phosphorylate 
it  at  seven  distinct  sites  in vivo.  All  of  these  phos-
phorylation  sites  contain  a  consensus  sequence  for 
proline-directed protein kinases. Phosphorylation of 
SRC-1 can also occur via Src kinase activity [48] and 
the mitogen-activated protein kinases (MAPK), ERK1 
and ERK2 [49]. Growth factors such as EGF, interleu-
kin-6  and  cAMP  can  all  induce  phosphorylation  of 
SRC-1 at specific consensus sites to increase its coac-
tivator  activity  for  ligand-bound  and  unliganded 
steroid  receptor  proteins.  It  has  been  shown  that 
cAMP-induced  phosphorylation  of  SRC-1  at  Thr1179 
and Ser1185 contribute to the steroid independent ac-
tivation of both ERα and PR [50], whilst EGF-induced 
phosphorylation of SRC-1 can increase PR-dependent 
transcription [49].  
 SRC-3  has  been  previously  associated  with  a 
specific  PTM  known  as  the  glycogen  synthase  3 
(GSK3β)  phospho-ubiquitin  clock  [51].  Initially,  this 
PTM was believed to be specific to SRC-3 however a 
recent study has shown that SRC-1 is subject to simi-
lar regulation [52]. The phospho-ubiquitin clock refers 
to the phosphorylation of the SRC protein by GSK3β 
which increases the rate of turnover and the interac-
tion of the SRC protein with a specific NR and then 
induces  the  ubiquitylation  of  the  protein  to  ensure 
that the transcriptional event terminates at an appro-
priate time  [53]. Current evidence suggests that the 
phospho-ubiquitin clock is conserved across all three 
p160  family  members  [52],  this  is  an  important 
mechanism  through  which  the  SRC  proteins  can 
maintain  tight  regulatory  control  over  their  many 
biological processes. 
Biological Functions of SRC-1  
1. The role of SRC-1 in reproduction and the 
uterus 
Numerous studies over the years have accumu-
lated evidence and shown that the SRC-1 protein is 
widely expressed in different tissues (Figure 2). SRC-1 
knockout mice were generated to investigate the basic Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
474 
biological functions of SRC-1 in these tissues [54]. The 
targeted deletion of the SRC-1 gene in mice disrupted 
its nuclear receptor binding and transcriptional acti-
vation functions and presumably, its recruited HAT 
activity from the secondary coactivators such as CBP, 
p300  and  p/CAF  [54].  Despite  these  disruptions, 
SRC-1  null  mice  exhibited  no  obvious  phenotype. 
Both male and female homozygotes were fertile and 
displayed a similar growth rate compared to the wild 
type  mice  [54].  However,  further  investigations  re-
vealed that steroid activity was partially impaired in 
SRC-1 null mice. Disruption of SRC-1 reduced estro-
gen-induced uterine growth; hence SRC-1 null mice 
achieved less than 60% uterine growth than that of the 
wild type mice when treated with estrogen. Further-
more,  it  was  observed  that  SRC-1  is  required  for 
maximal uterine response to steroid hormones in vivo 
[54].  SRC-1  is  required  for  estrogen  and  progester-
one-induced activities of ER and PR in the uterus but 
not in the breast [55]. Furthermore, mitogen-inducible 
gene 6 (Mig6) has been identified as a downstream 
target of PR and SRC-1 in the uterus. Mig6 is required 
to maintain endometrial homeostasis in response to 
estrogen and has also been proposed as an important 
protein in the suppression of endometrial cancer [56]. 
 SRC-1  is  also  expressed  in  the  glandular  and 
stromal cells of the normal endometrium. Immuno-
precipitation  assays  revealed  that  estrogen-induced 
SRC-1  interaction  with  endometrial  ER  only  oc-
curred during the proliferative phase of the menstrual 
cycle, indicating that SRC-1 has a regulatory role spe-
cific to this cycle phase [57, 58].  
 
 
 
 
Figure 2. The human tissues with SRC-1 protein expression. 
2. The role of SRC-1 in the prostate and testis 
 SRC-1 is also a known coactivator of the andro-
gen  receptor  (AR)  and  it  is  recruited  alongside 
SWI3-related gene product (SRG3) for AR-mediated 
cell  proliferation  during  prostate  development  and 
regeneration  [59].  SRC-1  null  male  mice  exhibit  re-
duced responsiveness to androgen stimulation versus 
controls. SRC-1 knockout mice also show a reduction 
in prostate and urethra weight compared with wild 
type  animals.  Histological  examination  of  testes  in 
SRC-1 null mice showed smaller glands without any 
apparent structural abnormalities [54]. 
3. The role of SRC-1 in the mammary gland 
 Mammary gland development is a tightly regu-
lated, steroid dependent process. In wild type female 
mice, mammary gland ducts grow extensively and fill 
the fat pad by 8 weeks of age [60]. However, in the 
absence of SRC-1, ductal density is reduced and the 
number and extent of branching occupies much less of 
the fat pad area in mice of a similar age. SRC-1 is re-
quired for normal mammary duct elongation during 
puberty and alveolar development during pregnancy. 
Alveoli number and size were reduced in SRC-1 null 
mice  compared  with  wild  type  mice  of  the  same 
pregnant stage, although significantly the null mice 
did retain the capacity to produce milk [54]. 
4. The role of SRC-1 in other organs 
 SRC-1 is critical for appropriate brain develop-
ment and function. In Purkinje cells (PCs) of the cer-
ebellum, SRC-1 is more highly expressed than other 
SRC  members.  SRC-1  deficiency  retards  PC  devel-
opment during embryogenesis and neonatal stages. 
Adult  SRC-1  null  mice  exhibit  moderate  motor 
learning deficiencies  [61]. The delay of PC devel-
opment  at  the  embryonic  and  neonatal  stages  is 
mainly attributed to both late birth and slow mi-
gration of SRC-1 knockout PC precursors [61].  
 SRC-1 is a functional coactivator of the thyroid 
receptor  (TR),  and  loss  of  SRC-1  activity  causes 
partial resistance to thyroid hormone signaling [37, 
62]. Simultaneous knockout of SRC-1 and thyroid 
hormone  receptor  proteins  (SRC-1/TRα  and 
SRC-1/TRβ knockout mice) caused more significant 
growth retardation than single knockout of either 
TRβ or TRα, suggesting SRC-1 is important for TRβ 
or TRα-mediated body growth [63]. 
 In addition, SRC-1 deletion led to skeletal re-
sistance to estrogen predominantly in the cancellous 
bones [64, 65]. Under both physiological and patho-
logical conditions, SRC-1 was shown to play an im-
portant role in the maintenance of bone mineral den-
sity by sex hormones and is necessary for protection Int. J. Biol. Sci. 2012, 8 
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against osteopenia and osteoporosis [66]. Interesting-
ly, a genetic polymorphic variant of the SRC-1 protein 
(SNP-1272S) was found to be associated  with a de-
crease in bone mineral density [52, 67]. 
 Finally, SRC-1 is an important mediator of the 
protective  effects  of  estrogen  in  the  cardiovascular 
system. SRC-1 is expressed in the endothelial cells and 
the  vascular  smooth  muscle  cells  (VSMCs)  of  the 
normal arterial wall. SRC-1 expression is also found in 
the  cells  of  neointima,  induced  by  vascular  injury. 
SRC-1-/- mice exhibit reduced vasoprotective capabili-
ties in the vascular wall, which manifests as enhanced 
neointima  formation  and  as  a  marked  increase  in 
VSMC  proliferation  in  response  to  vascular  injury 
[68]. Furthermore, SRC-1 is coexpressed with SRC-3 in 
the blood vessel wall and the roles of these two family 
members  demonstrate  considerable  functional  re-
dundancy with regards to the execution of estrogen 
induced vasoprotective mechanisms [69].  
5. Metabolic functions of SRC-1 
 The NR, PPARγ, is critical for the development 
of both white and brown adipose tissue [70]. SRC-1 
activity in the adipose tissue is dependent on PPARγ 
and  its  coactivator,  PPARγ  coactivator-1  (PGC-1). 
When  PGC-1  binds  to  PPARγ,  it  undergoes  a  con-
formational change and can complex with SRC-1 and 
CBP/p300, to significantly enhance the transcriptional 
activity of PPARγ in brown adipose tissue [71]. Inac-
tivation of SRC-1 impairs the thermogenic activity of 
PGC-1 in the brown adipose tissue, it decreases en-
ergy expenditure and increases susceptibility to obe-
sity following a high fat diet. The ratio of SRC-1 ex-
pression relative to SRC-2 also has a significant im-
pact on energy homeostasis as a loss of SRC-2 enables 
SRC-1 to bind PGC-1 with little or no competition. As 
a  result,  SRC-2-/-  mice  have  increased  thermogenic 
activity, they are also protected against obesity and 
demonstrate high insulin sensitivity [72]. SRC-1 also 
acts in conjunction with SRC-3 to selectively regulate 
the  expression  of  genes  involved  in  brown  adipose 
tissue development. SRC-1-/-/SRC-3-/- knockout mice 
have underdeveloped adipose tissue compartments, 
which are incapable of lipid storage and consequen-
tially,  demonstrate  defective  thermogenic  response 
mechanisms [73].  
 Finally, in the liver, SRC-1 controls hepatic glu-
cose production via its coactivation of the non steroi-
dal  C/EBPα  transcription  factor.  C/EBPα  signals 
through a feed-forward loop to transactivate pyruvate 
carboxylase, which is a crucial gene for the initiation 
of gluconeogenesis. SRC-1 null mice are hypoglyce-
mic in both fed and fasting states, it is thus suggested 
that C/EBPα is unable to function in the absence of 
SRC-1.  Hence,  SRC-1  has  a  key  role  in  the  mainte-
nance of glucose homeostasis in the liver [74]. SRC-1 
also functions in the liver to coactivate the LXRα/RXR 
heterodimer.  LXRα  is  commonly  involved  in  lipid 
homeostasis  and  fatty  acid  synthesis  in  the  hepato-
cytes.  In  this  context,  SRC-1  signals  in  conjunction 
with the LXRα/RXR heterodimer to upregulate tran-
scription  of  the  ABC  transporter  protein,  ABCA1, 
which  accelerates  fecal  cholesterol  disposal  by  de-
creasing  the  efficiency  of  cholesterol  absorption. 
DAX-1 is a member of the nuclear receptor superfam-
ily that can repress other NR-mediated transcription. 
In  the  liver,  DAX-1  directly  interacts  and  competes 
with SRC-1 to repress LXRα transcriptional activity in 
the liver and control lipid homeostasis [75]. The abil-
ity of coactivators to compete and synergistically reg-
ulate transcription in response to homeostatic signals 
is an important aspect of their basic biological func-
tions. 
6. Redundant functions with other SRC pro-
teins 
 Given the structural homology of the p160 fam-
ily  members,  it  is  expected  that  SRC-1  would  have 
certain  redundant  functions  with  SRC-2  and  SRC-3 
[76]. Genetic studies in mice have demonstrated par-
tial functional redundancy between SRC-1 and SRC-2 
with regards to postnatal survival and growth  [77]. 
Furthermore, analysis of SRC-2 ablation in the testes 
results in abnormal spermatogenesis, age-dependent 
degeneration of seminiferous epithelium, and disor-
der of cholesterol homeostasis. However, this pheno-
type is significantly worsened in SRC-2 null mice with 
heterozygous SRC-1 knockout [77]. 
 Further  compensatory  action  was  observed  in 
the  uterus  of  PRCre/+;SRC-2flox/flox  mouse,  where  the 
additional loss of SRC-1 resulted in the complete ab-
sence of a decidual response. This indicates that the 
co-expressed SRC-2 and SRC-1 in the uterus cooperate 
in progesterone-initiated transcriptional programs to 
coordinate decidualization [78]. 
 It  was  discovered  that  SRC-1  and  SRC-3  both 
function to support labyrinth  morphogenesis  of the 
placenta. The labyrinth is an important component of 
the  placenta  which  connects  the  maternal  blood  si-
nuses and fetal vascular networks. A double knockout 
of SRC-1 and SRC-3 increased proliferation of laby-
rinth  trophoblasts  and  progenitor  gene  expression 
whilst down-regulating the expression of differentia-
tion-related  genes.  Deficiency  of  SRC-1  and  SRC-3 
also affected the expression of several genes relevant 
to  placental  morphogenesis  and  glucose  transporta-
tion. It was also noted that labyrinths of SRC-1/SRC-3 Int. J. Biol. Sci. 2012, 8 
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knockout embryos were smaller than wild type and 
single knockout embryos [79]. 
 SRC-1 can also cooperate with SRC-3 to enable 
embryo  survival.  The  majority  of  SRC-1  and  SRC-3 
double-knockout embryos die by E13.5. In contrast, 
SRC-1  single  knockout  embryos  develop  normally 
and SRC-3 single knockout embryos only exhibit par-
tial lethality [79].  
The Role of SRC-1 in Breast Cancer 
 SRCs  are  expressed  at  low  levels  in  multiple 
tissues  fundamental  to  the  proper  growth  and  de-
velopment of these organs and SRCs often contribute 
to cancer in the same tissues. The general consensus as 
reported from both molecular and clinical studies of 
breast cancer is that SRC-1 has specific roles in the 
mediation  of  metastasis,  in  the  switch  from  steroid 
dependent to steroid independent regulation and in 
the prediction of disease recurrence. 
1. SRC-1 expression in human breast tumors 
 SRC-1 protein expression is very low in human 
mammary gland ductal epithelial cells although it is 
steadily detectable in the nuclei of mouse mammary 
ductal  epithelial  cells.  However,  SRC-1  protein  was 
detected  in  19%  to  34%  of  human  breast  tumors. 
SRC-1  expression  is  significantly  associated  with 
large,  high  grade  tumors,  HER2  positivity,  disease 
recurrence and resistance to endocrine therapy. SRC-1 
expression also serves as an independent predictor of 
disease-free survival (Table 1) [14, 80, 81]. 
 
Table 1. IHC Analysis of SRC-1 Protein Expression in Human Breast Cancer. 
References  SRC-1 Expres-
sion by IHC, 
(n) 
Molecular As-
sociation 
Pathological Association  Additional Observations 
Hudelist  
et al. 2003 
28% (25)  ER+, 
SRC-2+ 
No association between SRC-1 and 
normal or malignant cancer 
- 
Fleming  
et al. 2004a 
29% (52)  ERα+  Poor outcome         
Lymph node positive patients 
92% of recurrences were SRC-1 positive 
SRC-1 associated with resistance to endocrine 
therapy 
Fleming  
et al. 2004b 
26% (70)  HER2+ 
PEA3+ 
Reduced disease free survival  
Recurrence 
Significant predictor of time to disease re-
currence 
Myers  
et al.    2004 
19% (150)  HER2+ 
ER- 
Larger tumors (>35mm) 
Reduced disease free survival 
90% of recurrences were SRC-1 positive 
Significant predictor of disease free survival 
Myers  
et al.    2005 
24% (134)  HER2+ 
Ets-1+ 
Ets-2+ 
High grade tumors 
Recurrence 
Both Ets-1 and Ets-2 colocalize with SRC-1 in 
tumor cells 
SRC-1 associates with phospho-Raf 
Redmond  
et al. 2009 
34% (560) 
HER2+ 
COX2+ 
Distant    metastasis 
 
Reduced disease free survival  
Significant predictor of time to disease re-
currence 
Increased SRC-1 colocalization with ERα in 
Tamoxifen-treated recurrences 
McIlroy  
et al. 2010 
HOXC11+ 
S100+ 
SRC-1 and HOXC11 are strong predictors of 
reduced disease free survival in a Tamoxifen 
treated population 
McCartan  
et al. 2011 
ADAM22+  SRC-1 and ADAM22 are independent pre-
dictors of disease recurrence 
IHC immunohistochemistry; n, number of patient population; (+), positive association; (-), negative association; ER, estrogen receptor. 
 
 
2. The SRC-1-/-;MMTV-PyMT model 
 The role of SRC-1 in mammary tumor initiation, 
progression and metastasis has been investigated by 
knocking  out  SRC-1  in  the  MMTV-PyMT  (mouse 
mammary tumor virus-polyoma middle T) transgenic 
mice  [82].  Analysis  of  mammary  tumorigenesis  in 
SRC-1-/-;MMTV-PyMT  and  MMTV-PyMT  mice  re-
vealed that SRC-1 is not required for mammary tumor 
initiation and growth. However, SRC-1 does impact 
on the differentiation and polarized structuring of the 
mammary  epithelial  tumor  cells  in  the 
three-dimensional  culture  [82].  Furthermore,  SRC-1 
activity has been strongly associated with mammary 
tumor cell intravasation and metastasis to the lungs. 
Blood  samples  taken  from  MMTV-PyMT  mice 
showed a significantly higher number of mammary 
tumor  cells  in  the  circulation  than  that  from  the 
SRC-1-/-;MMTV-PyMT  mice,  indicating  that  SRC-1 
promotes migration of breast cancer cells and  inva-
sion of these tumor cells into the vascular system.  
 SRC-1  expressed  in  the  mammary  tumor  cells 
also upregulates the expression and secretion of col-
ony  stimulating  factor-1  (CSF-1)  to  facilitate  the  re-
cruitment  of  macrophages  to  the  mammary  tumor 
sites  [82].  Macrophage  recruitment  has  been  associ-Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
477 
ated with invasiveness and metastasis of breast tumor 
cells to local and distant sites [83]. At the tumor site, 
macrophages secrete factors such as EGF and TGF-1 
that stimulate proliferation and invasiveness of tumor 
cells [84]. Macrophages also induce angiogenesis via 
secretion of proangiogenic cytokines such as TNF- 
and  IL-8.  In  turn,  these  stimulate  c-Jun-NH2-kinase 
and NF signaling pathway to induce local release of 
the  proinvasive  angiogenesis-inducing  MMP  en-
zymes.  
 Importantly,  the  metastatic  nature  of  SRC-1  is 
intrinsic to the tumor cells as demonstrated by recip-
rocal  transplantation  of  MMTV-PyMT  and 
SRC-1-/-;MMTV-PyMT tumors into SRC-1-/- and wild 
type recipient mice [82]. In the MMTV-PyMT model, 
loss  of  SRC-1  also  correlated  closely  with  reduced 
expression of the HER2 oncogene as well as with re-
duced levels of the steroid independent transcription 
factor Ets2, thus further confirming the associations 
between SRC-1 and growth factor signaling effectors 
in breast cancer [82]. 
3. The SRC-1;MMTV-neu model 
 The  SRC-1-/-;MMTV-neu  mouse  breast  cancer 
model was generated by crossing MMTV-neu trans-
genic mice with SRC-1 knockout mice. In this model, 
SRC-1  deficiency  increased  tumor  latency  and  re-
duced tumor cell proliferation index and lung metas-
tasis. As observed in the SRC-1-/-;MMTV-PyMT mod-
el,  SRC-1-/-;MMTV-neu  tumors  were  also  more  dif-
ferentiated  than  the  MMTV-neu  tumors.  Molecular 
analysis demonstrated an increase in the expression of 
several cell cycle inhibitors [85]. 
 The  findings  from  both  SRC-1-/-;MMTV-PyMT 
and  SRC-1-/-;MMTV-neu  breast  cancer  models  indi-
cate that SRC-1 plays a crucial role in promotion of 
breast  cancer  metastasis,  while  in  the  MMTV-neu 
model  SRC-1  also  enhances  tumor  initiation  and 
growth, suggesting that the role of SRC-1 on tumor 
growth  may  be  specific  to  individual  onco-
gene-induced  tumorigenic  pathways.  In  addition, 
since the tumors from both models are ER negative, 
SRC-1 likely promotes tumorigenesis and metastasis 
in  these  models  through  estrogen-independent 
pathways. 
4. Growth factor signaling and SRC-1  
 SRC-1  is  highly  expressed  in  HER2  positive 
breast cancers [80, 81, 86] and has been shown to co-
activate Ets2, a transcription factor activated by the 
HER2-MAPK signaling pathway. Under the influence 
of HER2, Ets2 and SRC-1 are recruited to the promoter 
of  the  c-myc  oncogene.  In  turn,  c-myc  expression 
promotes breast tumor cell survival, metastasis and 
resistance to both Tamoxifen and aromatase inhibitors 
[87, 88]. 
 Simultaneous  overexpression  of  SRC-1  and 
HER2 frequently occurs and has important implica-
tions  in  tumor  cell  proliferation.  SRC-1  mediates 
overexpression  of  stromal  cell-derived  factor  alpha 
(SDF-1α) while HER2 signaling mechanisms mediate 
the stabilization of SDF-1α’s specific receptor CXCR4 
[89]. It has been reported that SDF-1a:CXCR4 signal-
ing complex is required for the proliferation of cancer 
cells at sites of metastasis [90]. The formation of the 
SDF-1a:CXCR4 complex is one example of the ability 
of  SRC-1  signaling  to  crosstalk  with  that  of  other 
pathways and therein promote disease progression.  
5. Mechanisms of SRC-1 action in breast can-
cer metastasis 
 A role for SRC-1 in breast cancer metastasis has 
been established and to date, two distinct mechanisms 
have been elucidated. In the first instance, SRC-1 im-
pacts  on  the  epithelial  to  mesenchymal  transition 
(EMT) and epithelial depolarization via regulation of 
the  EMT  transcription  factor  Twist.  In  the  second, 
SRC-1  upregulates  the  expression  of  integrin  α5  to 
promote cell migration and invasion.  
 Twist: EMT is characterized by the loss of epi-
thelial  differentiation  and  the  gain  of  mesenchymal 
properties within the cellular population. This transi-
tion enables tumor cells to invade and survive in the 
stromal tissues. In essence, EMT may be an early step 
towards  metastasis  and  is  characterized  by  certain 
gene expression changes [17, 91]. In vitro experiments 
from  the  wild  type  and  SRC-1  knockout  cell  lines 
show that SRC-1 inversely correlates with the major 
EMT  hallmark  protein,  E-cadherin.  Furthermore, 
SRC-1 regulates the EMT transcription factor, Twist, a 
known suppressor of E-cadherin. It serves as a master 
molecular switch of the EMT program [92]. 
 Observations  from  HER2-positive  cancer  cells 
suggest that the MAPK pathway controls the direct 
phosphorylation,  stabilization  and  accumulation  of 
Twist protein expression. This was further confirmed 
in tumor samples where HER2 positively correlated 
with  Twist  phosphorylation,  total  Twist  protein  ex-
pression and activity of the c-Jun N-terminal kinase 
(JNK). JNK is a member of the MAPK family. More-
over, Twist is a transcriptional target for SRC-1 and 
the  polyoma  enhancer  activator  3  (PEA3),  a  down-
stream MAPK effector [17]. Incidentally, these obser-
vations in HER2 positive tumors also correlate with 
negative PR status and are independent of ERα status. 
PR  negative  cancers  are  more  aggressive  and  have 
associations with resistance to therapy and bone me-Int. J. Biol. Sci. 2012, 8 
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tastasis hence substantiating the tumorigenic poten-
tial role of Twist in breast cancer [93].  
 Integrin  α5:  SRC-1  can  also  mediate  metastatic 
action  in  conjunction  with  the  non-steroidal  tran-
scription  factor  AP-1  and  the  tumor  microenviron-
ment.  Resident  fibroblasts  produce  abundant  extra-
cellular matrix (ECM) proteins to provide anchorage 
for tumor cell adhesion and migration  [94]. Hetero-
dimeric  integrin  transmembrane  receptors  bind  to 
ECM  proteins  to  transport  signals  bidirectionally 
across the cell membrane, allowing cells to respond to 
environmental  changes  [94].  In  breast  cancer,  these 
integrin  receptors  have  been  associated  with  tumor 
cell  survival,  growth  and  metastasis  in  an  anchor-
age-independent  manner.  In  particular,  the  hetero-
dimeric  receptor,  α5β1,  is  increased  in  malignant 
breast cancer and is associated with poor prognosis 
[95]. SRC-1 serves as a coactivator for the transcription 
factor AP-1, the two complexing together at the pro-
moter of the integrin α5 gene, enhances its transcrip-
tion. In the absence of SRC-1 cell adhesion and mi-
gration  via  the  ECM-integrin-focal  adhesion  kinase 
(FAK)  pathway  are  reduced.  The  downstream  sig-
naling components of this pathway are also signifi-
cantly reduced in the absence of SRC-1 and the integ-
rin α5 [16], suggesting that integrin α5 is a key target 
gene  of  SRC-1  in  its  efforts  to  orchestrate  the  local 
invasion and metastatic survival of breast cancer tu-
mor cells.  
6. SRC-1 and resistance to Tamoxifen therapy 
 SRC-1 has been increasingly cited with regards 
to the development of resistance to endocrine therapy 
in breast cancer. Resistance to endocrine therapy rep-
resents a serious clinical dilemma and is an increas-
ingly prevalent occurrence among breast cancer pa-
tients.  Tamoxifen  is  a  selective  estrogen  receptor 
modulator  (SERM)  and  is  the  most  common  an-
ti-estrogen  therapy  prescribed  for  pre-menopausal 
ERα-positive  breast  cancers.  Studies  carried  out  in 
HeLa  cells  where  Tamoxifen  is  an  agonist,  have 
shown that overexpression of SRC-1 further increases 
the activity of Tamoxifen [96]. Similarly, in the Ishi-
kawa endometrial cancer cell line where Tamoxifen is 
also agonistic, high levels of SRC-1 expression were 
reported  compared  to  the  MCF-7  breast  cancer  cell 
line  [97].  Interestingly,  src  kinase  activity  has  been 
shown to specifically enhance SRC-1 and CBP activity 
in these Ishikawa cells [48], thus associating high lev-
els  of  SRC-1  protein  and  growth  factor  signaling 
pathways with tissues that are receptive to the ago-
nistic  properties  of  Tamoxifen  [97].  In  addition,  a 
non-synonomous  small  nucleotide  polymorphism 
(SNP-P1272S) was identified in the DNA sequence of 
SRC-1, which decreased SRC-1 activity. Specifically, 
this study also demonstrated that the SNP-P1272S had 
a negative impact on the agonistic effects of Tamoxi-
fen  on  bone  mineral  density  in  post  menopausal 
women [52].  
 With regards to the development of resistance, it 
was  reported  that  SRC-1  overexpression  could  con-
vert Tamoxifen from a transcriptional repressor to a 
transcriptional activator in breast cancer  [98]. It has 
been shown that SRC-3 could compete with the Ta-
moxifen-recruited transcriptional repressor PAX and 
result in upregulation of HER2 expression [99]. The 
stoichiometry of PAX and SRC-3 was thus shown to 
dictate the efficacy of Tamoxifen treatment in breast 
cancer as HER2 and SRC-3 upregulation have been 
positively  associated  with  the  development  of  Ta-
moxifen  resistance  in  breast  cancer.  Similar  effects 
have  also  been  seen  with  NRs  other  than  ER,  as 
overexpression of SRC-1 is also capable of inducing 
PR activity in the presence of the PR antagonist RU486 
[100].  
 As therapeutic resistance becomes more preva-
lent, the ability to predict positive patient response to 
Tamoxifen  is  becoming  increasingly  important. 
Treatment with Tamoxifen itself has been shown to 
increase  the  expression  levels  of  both  SRC-1  and 
SRC-3 in multiple studies [101, 102]. It was observed 
that the expression of SRC-1, SRC-3 and multiple cell 
cycle and cell adhesion genes was increased, while the 
expression of apoptotic genes and PR was concomi-
tantly  downregulated  during  the  development  of  a 
Tamoxifen-resistant cell line. Loss of PR is indicative 
of  an  alteration  in  tumor  steroid  receptor  profile, 
which  is  a  common  feature  in  the  development  of 
Tamoxifen resistance. Interestingly, the SRC-1 protein 
level was decreased in the resistant cells once Tamox-
ifen treatment was stopped for a 12 months period 
[103]. It was also reported that the co-association of 
SRC-1 and SRC-3 with ER was increased in LY2 en-
docrine-resistant  breast  cancer  cells  following  Ta-
moxifen  treatment  in  comparison  with  endo-
crine-sensitive MCF-7 cells, and that the colocalization 
of SRC-1 and SRC-3 with ER was significantly en-
hanced in patients who have relapsed on endocrine 
treatment in comparison with those patients who did 
not undergo recurrence. Overall, analysis of the clin-
ical data suggest that SRC-1 is a strong independent 
predictor of reduced disease free survival and that the 
interactions of the p160 SRC proteins with ER can 
predict the response of patients to endocrine therapy 
[104].  
 An  aberrant  up-regulation  of  growth  factor 
pathways which target the activity of SRC proteins is 
a common feature in the development of an endocrine Int. J. Biol. Sci. 2012, 8 
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resistant  phenotype.  The  HER2  pathway  induces 
protein kinase A (PKA) to phosphorylate ERα at ser-
ine 305 in the presence of Tamoxifen. This phosphor-
ylation alters the orientation of ERα and SRC-1 and 
switches  Tamoxifen  to  an  ERα  agonist,  resulting  in 
RNA  Polymerase  II  recruitment  and  transcriptional 
initiation [105]. These findings were supported by a 
separate  study  in  which  Tamoxifen  resistance  was 
also  associated  with  ER  phosphorylation  at  serine 
305 [106]. 
 Additional  clinical  data  showed  an  increased 
co-association  of  SRC-1  with  MAPK-activated  tran-
scription  factors  PEA3  and  Ets2  in  a  Tamoxifen 
treated patient population [14, 86]. As expected, both 
of  these  co-associations  correlated  positively  with 
HER2 positivity in the same population. In agreement 
with the upregulation of c-myc by Ets2 and SRC-1 in 
cultured cells, this upregulation was also observed in 
the Tamoxifen-treated patient population. 
 More recent data has identified two more tran-
scription  factors  that  work  with  SRC-1.  Firstly, 
HOXC11, a member of the homeobox family of de-
velopmental  proteins  was  identified  as  a  functional 
binding partner for SRC-1 in Tamoxifen-resistant LY2 
cells.  Hox  family  proteins  have  been  implicated  in 
EGF-mediated migration and adhesion as well with 
the agonistic properties of Tamoxifen. Immunohisto-
chemical  analysis  of  a  Tamoxifen-treated  patient 
population  showed  increased  localization  and  ex-
pression  of  HOXC11  in  the  nuclei  of  tumor  cells. 
Strong  associations  were  also  observed  between 
HOXC11 and SRC-1 in the resistant LY2 cells com-
pared  to  the  Tamoxifen-sensitive  MCF-7  cells.  This 
observation was repeated in the patient population. 
Moreover, coexpression of HOXC11 with SRC-1 was 
noted as a superior predictor of poor clinical progno-
sis than any of the other classic parameters [15]. This 
study  also  recognized  S100  as  the  transcriptional 
target for the HOXC11 and SRC-1 complex. In breast 
cancer patients, the elevated levels of S100 signifi-
cantly  predicted  poor  disease  free  survival.  Since 
S100 is detectable in human serum, it can be poten-
tially  used  as  a  biomarker  to  predict  and  monitor 
disease progression. 
 Secondly, SRC-1 interacts with the transcription 
factor  MYB  to  directly  regulate  ADAM22,  a 
non-protease member of the ADAM family of disin-
tegrins  [107].  Molecular  analysis  carried  out  in  Ta-
moxifen-resistant  cell  lines  discovered  a  role  for 
ADAM22 in cellular migration and differentiation. In 
addition,  expression  of  ADAM22  mRNA  was  in-
creased  in  the  Tamoxifen-resistant  tumors  in  xeno-
graft mouse models. Furthermore, ADAM22 expres-
sion was identified by immunohistochemical analysis 
in  a  clinical  patient  population  as  an  independent 
predictor of poor disease free survival [107]. ADAM22 
has  also  been  proposed  as  a  potential  therapeutic 
target as its migratory action can be inhibited follow-
ing treatment with its ligand LGI1 [107]. 
7. SRC-1 and resistance to aromatase inhibitor 
therapy 
 SRC-1 activity has been found to be associated 
with  resistance  to  aromatase  inhibitors  (AIs).  Like 
Tamoxifen resistance, AI resistance is also marked by 
a shift in cancer cell signaling from steroid depend-
ency towards dependency on peptide growth factors. 
In AI resistant cell lines, loss of SRC-1 improved cells’ 
ability to differentiate while reducing their migratory 
capacity. Interestingly, loss of ER in these cells failed 
to impact on migration. This indicates that SRC-1 may 
also act in a steroid independent manner to promote 
AI resistance. In AI-resistant cells, SRC-1 also interacts 
with MAPK-activated Ets2 transcription factor. Spe-
cifically,  SRC-1  and  Ets2  are  recruited  to  the  c-myc 
and MMP9 promoters upon AI (Letrozole) treatment. 
Importantly, in an AI-treated patient population with 
two  thirds  of  SRC-1-positive  and  one  third  of 
SRC-1-negative  primary  tumors,  all  AI-treated  pa-
tients  with  disease  relapse  from  original 
SRC-1-negative  tumors  presented  AI-resistant 
SRC-1-positive  tumors.  This  finding  has  important 
and  exciting  implications  for  the  specific  ability  of 
SRC-1  to  advance  metastasis  in  AI-treated  breast 
cancer [88]. 
SRC-1 in Prostate Cancer 
 SRC-1  has  been  linked  to  prostate  cancer  and 
extensively  evaluated  as  an  AR  coactivator  in  both 
androgen-dependent  and  independent  disease.  In 
localized,  androgen-dependent  tumors,  increased 
SRC-1 expression correlates with lymph node metas-
tasis [108]. Ablation of SRC-1 in androgen-dependent 
LNCaP  prostate  cancer  cells  represses  activation  of 
AR target genes and reduces AR-dependent cellular 
proliferation [108]. Furthermore, in CV1 cells, SRC-1 
overexpression  increases  the  androstenedi-
one-induced AR activity [109].  
 SRC-1 also has a role in androgen-independent 
prostate  cancer.  Although  one  clinical  study  found 
SRC-1  mRNA  expression  was  lower  in  thera-
py-resistant prostate cancer compared with untreated 
patients [110], others evaluating tumors from resistant 
patients  found  SRC-1  expression  significantly  in-
creased  in  hormone-refractory  tumors  compared  to 
androgen-dependent tumors or benign prostatic hy-
perplasia  [109,  111].  Re-activation  of  AR-mediated 
transcriptional programs in the absence of androgen Int. J. Biol. Sci. 2012, 8 
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is critical for the growth and survival of the majority 
of  castration-resistant  tumors.  The  elevated  expres-
sion of SRC-1 in these prostate tumors raises a possi-
bility that SRC-1 may support androgen-independent 
and  AR-mediated  transcription  and  promote  hor-
mone-refractory  tumor  growth.  In  support  of  this 
idea, CWR22 human prostate cancer cells xenografted 
into mice have decreased SRC-1 expression immedi-
ately following castration, but have significantly in-
creased SRC-1 expression at the time of tumor relapse 
[109]. In androgen-independent C4-2 prostate cancer 
cells that depend on AR for proliferation, knockdown 
of SRC-1 significantly reduced growth and AR target 
gene  expression.  In  contrast,  knockdown  of  SRC-1 
had no effect on the growth of the AR-negative PC-3 
and  DU145  prostate  cancer  cell  lines  [108].  Finally, 
SRC-1 is involved in ligand-independent activation of 
AR  by  IL-6,  a  cytokine  that  regulates  proliferation, 
apoptosis and angiogenesis in prostate cancer [112].  
 The direct in vivo contribution of SRC-1 to pros-
tate cancer was investigated through the use of ge-
netically engineered mouse models. The SRC-1 gene 
was deleted in TRAMP mice, which harbor the onco-
genic SV40 T/t antigen transgene driven by the pros-
tate  epithelium-specific  probasin  promoter  [113]. 
Tumor  mass,  histology  and  biomarkers  in  cancers 
from these mice were assessed at various ages; how-
ever  no  significant  difference  in  tumor  initiation  or 
progression between SRC1-/- and wild type TRAMP 
mice was found. Interestingly, expression of SRC-3, 
was  significantly  elevated  thus  indicating  that,  in 
TRAMP mice, SRC-1 and SRC-3 may have analogous 
functions and SRC-3 over-expression may be able to 
compensate for SRC-1 deficiency [113]. Although its 
contribution  to  tumourigenesis  is  non-essential  in 
TRAMP mice, the significant findings in human sam-
ples and cell lines suggest that SRC-1 may still be a 
critical prostate cancer mediator.  
SRC-1 Expression in Other Cancers  
1. Endometrial cancer 
 SRC-1  dysregulation  has  been  reported  in  en-
dometrial  cancer.  SRC-1  mRNA  levels  are  signifi-
cantly increased in malignant endometrial cancer and 
the  high  expression  of  SRC-1  positively  correlates 
with ERα and PR expression. However, no significant 
correlation was found between SRC-1 mRNA expres-
sion and grade, stage, or depth of myometrial inva-
sion [114]. Conversely, SRC-1 expression was report-
ed as reduced in the less aggressive endometrial hy-
perplasia  and  in  endometrial  carcinoma  compared 
with normal glandular cells in the proliferative phase 
[115].  
2. Thyroid cancer 
 In thyroid cancer, SRC-1 is expressed in epithe-
lial tumor cells. In non-anaplastic tumors, SRC-1 ex-
pression  is  significantly  associated  with  HER2  ex-
pression, and together their levels correlate with poor 
cellular differentiation, capsular invasion and disease 
progression.  In  anaplastic  thyroid  tumors,  SRC-1  is 
expressed  in  87%  of  samples  and  again  positively 
correlates with reduced survival rate (p<0.001) [116] .  
3. Cutaneous melanoma 
 Analogous  to  that  observed  in  breast  cancer, 
SRC-1 also serves as a coactivator for HOXC11 to up-
regulate S100 in cutaneous melanomas. Serum levels 
of S100 have been proposed as a marker of tumor 
burden,  predicted  poor  response  to  treatment  and 
poor  prognosis  in  melanoma  patients  [117,  118]. 
Higher expression levels and co-association of SRC-1 
and HOXC11 were reported in malignant melanoma 
compared to benign nevi. The same was also observed 
in a metastatic melanoma cell line. Interestingly, dis-
ruption  of  HOXC11  and  SRC-1-regulated  S100  in 
malignant cells using the dual Src/Abl inhibitor, De-
satinib,  can  interfere  with  the  phosphorylation  of 
SRC-1 by Src kinase [119]. This may represent a new 
therapeutic approach for the treatment of advanced 
melanoma. 
SRC Proteins as Potential Therapeutic 
Targets 
 Given the wide-reaching oncogenic effects of the 
SRC proteins, particularly SRC-1 and SRC-3, signifi-
cant strides are being made to elucidate their potential 
as  effective  biological  therapeutic  targets.  Previous 
reluctance to pursue SRCs as therapeutic targets arose 
from their large size, lack of structural conformity and 
the  absence  of  any  high  affinity  ligand-binding  do-
mains. However, new proof of principle experiments 
has challenged this view and shown that small mol-
ecule  inhibitors  (SMIs)  such  as  gossypol,  a  natural 
polyphenol, are capable of reducing SRC-1 and SRC-3 
proteins in MCF-7 and other cancer cell lines. Inter-
estingly, SRC-2 was not susceptible to the inhibitory 
effects of gossypol treatment. Gossypol was shown to 
physically  interfere  with  the  binding  between  the 
SRC-3  RID  and  the  ERα  ligand  binding  domain. 
However,  the  resultant  degradation  of  SRC-1  and 
SRC-3  occurred  independently  of  a  proteasomal 
mechanism. This ability of gossypol to reduce SRC-1 
and  SRC-3  proteins  was  also  maintained  inde-
pendently of the various ER ligands such as estrogen, 
Tamoxifen and ICI 182,780. Moreover, the gossypol 
action  is  independent  of  ERα  as  it  also  degrades Int. J. Biol. Sci. 2012, 8 
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SRC-3  in  ERα  negative  cancer  cells.  Treatment  of 
cancer cells with gossypol also resensitized the cells to 
MEK, EGF and IGF pathway inhibitors. Of significant 
importance, this form of SMI treatment is preferen-
tially toxic to cancerous cells and is relatively selective 
for SRC-1 and SRC-3 [120]. This work is the first to 
show that SRC proteins are accessible to SMI-based 
chemotherapy.  Continued  research  into  this  area 
could  have  significant  implications  for  treatment  of 
cancers, especially those resistant to current therapies.  
 
 
 
Figure 3. SRC-1 coregulator activity in breast cancer. SRC-1 is susceptible to activation by the cytokine, steroid or growth factor 
pathways. These pathways encode the SRC -1 protein to coactivate a specific transcription factor in order to mediate specific tran-
scriptional events within the nucleus. The schematic diagram illustrates the potential transcriptional binding partners of SRC-1 and their 
respective downstream effector targets. Under the influence of either steroid dependent or steroid independent signaling networks, 
SRC-1 will interact with different transcription factors to form varying complexes for transcriptional regulation of tumor cell processes 
that will promote an increasingly aggressive and resistant tumor phenotype. EMT: epithelial mesenchymal transition; FAC: focal adhesion 
complex. 
 
Conclusion 
 The discovery and characterization of the p160 
SRC family have revolutionized the field of molecular 
endocrinology and endocrine-related oncology. SRCs 
have  been  described  as  “the  powerhouses  of  tran-
scription”  and  have  been  rightfully  reclassified  as 
“master genes” on the basis of their ability to bind 
across unrelated families of transcription factors and 
coordinate the regulation of multiple genes in multi-
ple complex physiological states [121]. SRC-1 epito-
mizes all of these master qualities and the recent work 
outlined in this review highlights this transcriptional 
coactivator as a key player in normal development, 
multiple  cellular  signaling  crosstalk,  promoting  re-
sistance to endocrine treatments and coordination of 
tumor cell metastasis. Int. J. Biol. Sci. 2012, 8 
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